Wellington Management Group
KPTI icon

Wellington Management Group’s Karyopharm Therapeutics KPTI Stock Holding History

Wellington Management Group’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-37,453
Closed -$1.01M – 1852
2023
Q2 		$1.01M Buy
37,453
+21,850
+140% +$941K ﹤0.01% 1602
2023
Q1 		$910K Buy
15,603
+362
+2% +$17.9K ﹤0.01% 1681
2022
Q4 		$777K Sell
15,241
-1,101
-7% -$76.3K ﹤0.01% 1699
2022
Q3 		$1.34M Buy
16,342
+3,253
+25% +$243K ﹤0.01% 1605
2022
Q2 		$886K Hold
13,089
– – ﹤0.01% 1700
2022
Q1 		$1.45M Sell
13,089
-348
-3% -$43.4K ﹤0.01% 1668
2021
Q4 		$1.3M Buy
+13,437
New +$1.34M ﹤0.01% 1759
2021
Q3 		– Sell
-39,733
Closed -$6.15M – 2211
2021
Q2 		$6.15M Sell
39,733
-88,118
-69% -$12.8M ﹤0.01% 1439
2021
Q1 		$20.2M Sell
127,851
-17,430
-12% -$3.67M ﹤0.01% 1070
2020
Q4 		$33.7M Buy
145,281
+29,101
+25% +$6.74M 0.01% 893
2020
Q3 		$25.4M Buy
116,180
+16,013
+16% +$3.92M 0.01% 895
2020
Q2 		$28.5M Buy
100,167
+6,924
+7% +$2.05M 0.01% 843
2020
Q1 		$26.9M Buy
93,243
+2,668
+3% +$736K 0.01% 799
2019
Q4 		$26M Sell
90,575
-293,270
-76% -$63.6M 0.01% 919
2019
Q3 		$55.4M Sell
383,845
-178,716
-32% -$24.2M 0.01% 702
2019
Q2 		$50.5M Buy
562,561
+70
+0% +$5.62K 0.01% 752
2019
Q1 		$49.3M Buy
562,491
+14,706
+3% +$1.63M 0.01% 746
2018
Q4 		$77M Sell
547,785
-9,833
-2% -$1.66M 0.02% 582
2018
Q3 		$142M Buy
557,618
+6,509
+1% +$1.8M 0.03% 473
2018
Q2 		$140M Buy
551,109
+97,217
+21% +$24M 0.03% 472
2018
Q1 		$91.4M Buy
453,892
+51,048
+13% +$10.2M 0.02% 599
2017
Q4 		$58M Sell
402,844
-16,374
-4% -$2.63M 0.01% 730
2017
Q3 		$69M Buy
419,218
+14,978
+4% +$2.15M 0.02% 659
2017
Q2 		$54.9M Buy
404,240
+18,870
+5% +$2.79M 0.01% 707
2017
Q1 		$74.2M Buy
385,370
+3,609
+0.9% +$579K 0.02% 597
2016
Q4 		$53.8M Buy
381,761
+97,829
+34% +$13.2M 0.01% 697
2016
Q3 		$41.4M Buy
283,932
+184,556
+186% +$22.2M 0.01% 750
2016
Q2 		$10M Buy
99,376
+14,744
+17% +$1.92M ﹤0.01% 1141
2016
Q1 		$11.3M Buy
84,632
+73,068
+632% +$8.06M ﹤0.01% 1106
2015
Q4 		$2.3M Buy
11,564
+229
+2% +$49.6K ﹤0.01% 1588
2015
Q3 		$1.79M Buy
11,335
+708
+7% +$189K ﹤0.01% 1669
2015
Q2 		$4.34M Sell
10,627
-1,099
-9% -$475K ﹤0.01% 1444
2015
Q1 		$5.38M Sell
11,726
-2,690
-19% -$1.16M ﹤0.01% 1429
2014
Q4 		$8.09M Sell
14,416
-7,452
-34% -$4.23M ﹤0.01% 1309
2014
Q3 		$11.5M Sell
21,868
-677
-3% -$382K ﹤0.01% 1197
2014
Q2 		$15.7M Sell
22,545
-2,974
-12% -$1.38M ﹤0.01% 1118
2014
Q1 		$11.8M Sell
25,519
-8,162
-24% -$4.14M ﹤0.01% 1196
2013
Q4 		$11.6M Buy
+33,681
New +$9.3M ﹤0.01% 1191

Other funds holding KPTI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Wellington Management Group's KPTI Position: Q3 2023 in Review

Wellington Management Group sold out of Karyopharm Therapeutics (KPTI) in Q3 2023, closing a stake of 37,453 shares — an estimated $1.01M sold.

Wellington Management Group first reported a position in KPTI in Q4 2013 and held it in 38 quarters. The position peaked at $142M in Q3 2018. 118 funds tracked by Wall St. Rank hold KPTI as of Q3 2023.

  • Wellington Management Group reported no remaining Karyopharm Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Wellington Management Group sold 37,453 Karyopharm Therapeutics shares in Q3 2023, an estimated $1.01M.
  • Wellington Management Group first reported a position in Karyopharm Therapeutics in Q4 2013 and held it in 38 quarters.
  • Wellington Management Group's Karyopharm Therapeutics position peaked at $142M in Q3 2018.
  • 118 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2023.

Based on Wellington Management Group's 13F filing for Q3 2023, filed 14 Nov 2023.